Michinori Ogura

TL;DR: KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile, and further investigation of KW-761 for treatment of ATL and other T-cell neoplasms is warranted.

TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).

TL;DR: It is suggested that Epstein-Barr virus-associated LPD without immunodeficiency mainly occurs in elderly patients, and there was a significant difference in prognosis between the group with polymorphic LPDs and the one with large cell lymphomas.

TL;DR: This novel human megakaryoblastic cell line was established from the bone marrow of a patient with blast crisis of Philadelphia (Ph1) chromosome-positive chronic myelogenous leukemia and may provide a useful model for the study of humanMegakaryopoiesis and of the biosynthetic mechanisms of proteins unique tomegakaryocytic lineage.

TL;DR: KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL, and subsequent phase II studies at the 1.0 mg/kg dose are thus warranted.